The use of semaglutide, a glucagon-like peptide 1 receptor agonist (GLP-1 RA), is not associated with an increased risk for ...

Semaglutide offers a multifaceted approach to type 2 diabetes treatment, enhancing insulin release and reducing blood sugar ...

THURSDAY, Nov. 7, 2024 (HealthDay News) -- Expanding access to obesity medications such as glucagon-like peptide 1 (GLP-1) receptor agonists and dual gastric inhibitory polypeptide and GLP-1 receptor ...

Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide ...

The FDA is evaluating supply and demand and monitoring for patient safety. Semaglutide is a medication that mimics the ...

Now, there is also Ozempic-before-baby. Unplanned pregnancies are still regularly being reported among people using ...

For patients with opioid use disorder (OUD) and alcohol use disorder (AUD), prescriptions of glucose-dependent insulinotropic polypeptide (GIP) and/or glucagon-like peptide-1 receptor agonists (GLP-1 ...

Researchers found that adolescents treated with a glucagon-like peptide 1 receptor agonist (GLP1R) for obesity experienced ...

With the rising popularity of glucagon-like peptide-1 agents for treating obesity, many bariatric surgery programs across the ...

A new study published in the New England Journal of Medicine showed that once-weekly injectable semaglutide led to ...

GLP-1 RAs can decrease the risk for developing early-onset colorectal cancer (EO-CRC) in patients with diabetes regardless of weight.

Tirzepatide, known under the brand name Mounjaro is prescribed for type 2 diabetes, but has been shown in clinical trials to ...